


RACURA
ONCOLOGY

For personal use only

ASX:RAC

# Quarterly Report & 4C

## September 2026

For personal use only

## ASX Announcement

# September 2026 Quarterly Activities Report & Appendix 4C

- **First patient safely treated with RC220 & osimertinib in the HARNESS-1 trial for patients with EGFR-mutated non-small cell lung cancer**
- **Phase 1 CPACS trial expands to South Korea, allowing for accelerated patient recruitment and trial progress**
- **Ethics approval received for additional HARNESS-1 sites in NSW and Victoria, supporting greater patient access and faster clinical trial recruitment**
- Strong cash balance of $30.7m at 30 September 2026

**22 October 2026**

Racura Oncology Ltd ("Racura" or the "Company") is pleased to release its Q1 FY2027 report for the period ending 30 September 2026. The Company's cash and cash equivalents totalled $30.7 million at the end of the quarter, with 80% of spending ($2.46m) directed toward research and development (R&D) and drug manufacturing activities. A strong cash balance places Racura in an excellent position to fund all committed activities into mid-CY2028.

During the quarter, Racura continued to make significant progress across its clinical programs. In July, Racura expanded the HARNESS-1 lung cancer trial through additional ethics approvals, enabling the activation of new Australian clinical trial sites, and reported positive initial safety data from the first patient treated with RC220 in combination with osimertinib. The Company also received international recognition for its Cardioprotection and Anticancer Synergy (CPACS) program through acceptance for presentation at the Global Cardio-Oncology Summit. In September, Racura expanded the global footprint of the CPACS trial through the activation of clinical trial sites in South Korea, while new preclinical data further validating the ability of RC220 to inhibit MYC gene transcription were accepted for presentation at the *Frontiers in Cancer Science Conference* in Singapore.

## Management commentary

Chief Executive Officer and Managing Director Dr Daniel Tillett commented*: "We have made solid progress with our clinical programs with both the Phase 1 HARNESS-1 and CPACS trials clearing their first dose cohorts without any dose-limiting toxicities. With the expansion of CPACS into South Korea and $30.7 million in cash, Racura is well funded to continue advancing RC220 into mid-CY2028."*

For personal use only

## Key events of the quarter

- On 3 July 2026, Racura announced that Bellberry Human Research Ethics Committee had approved the HARNESS-1 lung cancer clinical trial, enabling additional Australian clinical trial sites to participate in the study. Following this approval, Chris O'Brien Lifehouse and Austin Health progressed to governance and start-up activities, supporting increased patient recruitment and the continued evaluation of RC220 in combination with osimertinib for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
- On 9 July 2026, Racura announced that its CPACS Phase 1 trial had been selected for presentation at the 2026 Global Cardio-Oncology Summit in the United States. The presentation will provide an update on the ongoing evaluation of RC220 in combination with doxorubicin in patients with advanced solid tumours and highlight growing international interest in the program's potential cardioprotective and anticancer benefits.
- On 29 July 2026, Racura announced that the first patient treated with RC220 and osimertinib in the HARNESS-1 trial had completed safety review with no dose-limiting toxicities or treatment-related safety concerns identified during the safety observation period. The independent Safety Review Committee recommended continuation of the trial and enrolment of an additional patient at the same dose level before further dose escalation.
- On 11 August 2026, Racura received a further $117,875 R&D Tax Incentive refund from the Australian Taxation Office for $243,041 of eligible overseas R&D activities undertaken during the financial year ended 30 June 2025 (FY2025). This additional refund brings the Company's total FY2025 R&D Tax Incentive refund to $2,905,348 following the earlier refund of $2,787,473 for eligible Australian R&D activities in FY2025 (ASX announcement: 27 Nov 2025).
- On 1 September 2026, Racura announced the activation of its first South Korean clinical trial site for the CPACS Phase 1 trial evaluating RC220 in combination with doxorubicin in patients with advanced solid tumours. Additional Korean sites were scheduled to open shortly thereafter, with the expanded site network expected to accelerate patient recruitment and trial progress.
- On 8 September 2026, Racura announced that new preclinical data supporting the G4-binding mechanism of action of (E,E)-bisantrene and inhibition of MYC gene transcription had been accepted for presentation at the 2026 Frontiers in Cancer Science Conference in Singapore. The findings further support the scientific rationale for RC220 and its ongoing clinical development across the Company's EMILI, HARNESS and CPACS programs.

## Other news from the quarter

- Dr Rodney Cusack and Dr Feroz Ahmad attended the Thoracic Oncology Group of Australasia Annual Scientific Meeting in Melbourne from 15–17 July 2026. The meeting provided an

opportunity to engage with clinicians, researchers and industry stakeholders and discuss developments relevant to the HARNESS-1 program.

- Vanessa Neve and Shinam Garg joined Racura as Clinical Project Managers, focusing on the HARNESS-1 and EMILI trials, respectively. Both bring extensive experience in clinical trial operations, project management, site oversight and study execution, and both have already made valuable contributions to advancing the Company's clinical development programs.
- Dr Chris Goon joined Racura as Associate Medical Director, bringing extensive experience in clinical medicine, oncology drug development and the management of clinical trials. Dr Goon will support the ongoing advancement of clinical development programs and contribute to the Company's clinical and medical strategy.

## Post-quarter news

- On 5 October 2026, Racura announced that its Annual General Meeting will be held on 23 November 2026 from 11AM–12PM at the State Library of New South Wales.
- On 7 October 2026, Racura presented clinical progress from the ongoing CPACS Phase 1 trial at the 2026 Global Cardio-Oncology Summit in Virginia, USA. The presentation highlighted successful completion of the first dose cohort with no dose-limiting toxicities observed and confirmed progression to the next RC220 dose level, with patient enrolment continuing across Australia, Hong Kong and South Korea.
- On 12 October 2026, Racura announced that the Safety Review Committee had cleared the Phase 1 HARNESS-1 trial to escalate RC220 to the next planned dose level of 100 mg/m² following a review of safety data from Cohort 1. No dose-limiting toxicities or treatment-related safety concerns were identified in either patient treated at the 50 mg/m² dose level, supporting continued evaluation of RC220 in combination with osimertinib for patients with EGFR-mutated NSCLC.

For personal use only

## Summary of cash flow and quarterly activity

As of 30 September 2026, Racura held cash and cash equivalents of $30.74 million.

## Listing rule 4.7C.3

Payments during the quarter to Related Parties amounted to $199k, comprising payments of salaries and superannuation to Executive Directors of $157k and board fees to Non-Executive Directors of $42k.

## Shareholders by holding range as of 30 September 2026

Racura is pleased to report that in the quarter the total number of shareholders with greater than 100,000 shares had increased over the previous quarter.

| Holding Ranges | Holders | Total Units | % Issued Capital |
|---|---|---|---|
| Above 0 up to and including 1,000 | 4,067 | 1,662,952 | 0.85% |
| Above 1,000 up to and including 5,000 | 2,740 | 6,826,720 | 3.48% |
| Above 5,000 up to and including 10,000 | 837 | 6,275,947 | 3.20% |
| Above 10,000 up to and including 100,000 | 1,646 | 52,739,043 | 26.90% |
| Above 100,000 | 316 | 128,564,278 | 65.57% |
| Total | **9,606** | **196,068,940** | **100.00%** |

For personal use only

For personal use only

## Top 20 holders as of 30 September 2026

Racura is pleased to share the current Top 20 shareholders as of 30 September 2026. Shareholders can expect regular updates in future quarterly reports.

| Position | Holder | Holding | % IC |
|---|---|---|---|
| 1 | DR DANIEL TILLETT | 20,094,730 | 10.25% |
| 2 | MR PHILLIP RICHARD PERRY | 7,421,138 | 3.79% |
| 3 | MR MARK PHILLIP JUAN | 6,058,876 | 3.09% |
| 4 | DR BORJE SVEN ANDERSSON | 3,750,005 | 1.91% |
| 5 | THE TRUST COMPANY (AUSTRALIA) LIMITED <MOF A/C> | 3,420,000 | 1.74% |
| 6 | BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT> | 2,374,654 | 1.21% |
| 7 | KUDOSS INVESTMENTS PTY LTD <AITKEN GLOBAL FAMILY A/C> | 2,314,450 | 1.18% |
| 8 | MR PHILLIP RICHARD PERRY & MRS TETYANA PERRY <DONESKA SUPER FUND A/C> | 2,068,500 | 1.06% |
| 9 | MR SANDOR HELBY | 2,050,000 | 1.05% |
| 10 | MR KIMBERLEY ROSS GARTRELL & MRS JENNIFER MARGARET GARTRELL <K&J GARTRELL SUPER FUND A/C> | 1,755,000 | 0.90% |
| 11 | MR ALAN GILES SAURAN | 1,333,888 | 0.68% |
| 12 | MR ANTHONY JAMES ROBINSON <THE PEEKO FAMILY NO 86 A/C> | 1,267,055 | 0.65% |
| 13 | SURPION PTY LTD <M W SUHR & CO A/C> | 1,264,000 | 0.64% |
| 14 | MS MARINELLA MESSINA | 1,187,044 | 0.61% |
| 15 | CITICORP NOMINEES PTY LIMITED | 1,172,617 | 0.60% |
| 16 | MR BRIAN JAMES WALKER | 1,168,110 | 0.60% |
| 17 | MR MARK PHILLIP JUAN | 1,149,164 | 0.59% |
| 18 | MR BEAU THOMAS ROBINSON <BEAU ROBINSON INVSTMNT A/C> | 966,760 | 0.49% |
| 19 | 3RD MAN RISK CONSULTING PTY LIMITED | 815,000 | 0.42% |
| 20 | MR ROSS EARL HENRY | 800,000 | 0.41% |
| | Total | 62,430,991 | 31.84% |
| | Total issued capital – selected security class(es) | 196,068,940 | 100.00% |

-ENDS-

For personal use only

## About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 2b/3 clinical-stage biopharmaceutical company with a mission to silence cancer.

The Company's lead asset, (E,E)-bisantrene, is a small-molecule anticancer agent that binds G4-DNA and RNA structures and potently inhibits MYC gene expression, a key cancer target dysregulated in up to 70% of cancers. Bisantrene has a long history of demonstrated therapeutic activity in cancer patients with a well-characterised safety profile. Recent discoveries have supported composition-of-matter and other patent filings that, if granted, could provide up to 20 years of protection for (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 2b/3 pivotal clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for patients with solid tumours.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements, please visit our Interactive Announcements page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

Cherie.hartley@irdepartment.com.au

RACURA ONCOLOGY LIMITED (RAC)

# Appendix 4C

# Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

RACURA ONCOLOGY LIMITED (RAC)

| **ABN** | **Quarter ended ("current quarter")** |
|---|---|
| 61 149 318 749 | 30 September 2026 |

| **Consolidated statement of cash flows** | | **Current quarter $A'000** | **Year to date (3 months) $A'000** |
|---|---|---|---|
| **1.** | **Cash flows from operating activities** | | |
| 1.1 | Receipts from customers | - | - |
| 1.2 | Payments for | | |
| | (a) research and development | (2,739) | (2,739) |
| | (b) product manufacturing and operating costs | (243) | (243) |
| | (c) advertising and marketing | (104) | (104) |
| | (d) leased assets | - | - |
| | (e) staff costs | (503) | (503) |
| | (f) administration and corporate costs | (564) | (564) |
| 1.3 | Dividends received (see note 3) | - | - |
| 1.4 | Interest received | 496 | 496 |
| 1.5 | Interest and other costs of finance paid | - | - |
| 1.6 | Income taxes paid | - | - |
| 1.7 | Government grants and tax incentives | 115 | 115 |
| 1.8 | Other (provide details if material) | - | - |
| **1.9** | **Net cash from / (used in) operating activities** | **(3,542)** | **(3,542)** |

| | | | |
|---|---|---|---|
| **2.** | **Cash flows from investing activities** | | |
| 2.1 | Payments to acquire or for: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | (13) | (13) |
| | (d) investments | - | - |

For personal use only

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (3 months) $A'000 |
|---|---|---|---|
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.2 | Proceeds from disposal of: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | - | - |
| | (d) investments | - | - |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.3 | Cash flows from loans to other entities | - | - |
| 2.4 | Dividends received (see note 3) | - | - |
| 2.5 | Other (provide details if material) | - | - |
| **2.6** | **Net cash from / (used in) investing activities** | **(13)** | **(13)** |

| | | | |
|---|---|---|---|
| **3.** | **Cash flows from financing activities** | | |
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | - | - |
| 3.2 | Proceeds from issue of convertible debt securities | - | - |
| 3.3 | Proceeds from exercise of options | - | - |
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | - | - |
| 3.5 | Proceeds from borrowings | - | - |
| 3.6 | Repayment of borrowings | - | - |
| 3.7 | Transaction costs related to loans and borrowings | - | - |
| 3.8 | Dividends paid | - | - |
| 3.9 | Other (share buy-back) | - | - |
| **3.10** | **Net cash from / (used in) financing activities** | **-** | **-** |

| | | | |
|---|---|---|---|
| **4.** | **Net increase / (decrease) in cash and cash equivalents for the period** | | |
| 4.1 | Cash and cash equivalents at beginning of period | 34,290 | 34,290 |
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | (3,542) | (3,542) |

For personal use only

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (3 months) $A'000 |
|---|---|---|---|
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | (13) | (13) |
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | - | - |
| 4.5 | Effect of movement in exchange rates on cash held | - | - |
| **4.6** | **Cash and cash equivalents at end of period** | **30,735** | **30,735** |

| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter $A'000 | Previous quarter $A'000 |
|---|---|---|---|
| 5.1 | Bank balances | 2,235 | 3,290 |
| 5.2 | Call deposits | 28,500 | 31,000 |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (provide details) | - | - |
| **5.5** | **Cash and cash equivalents at end of quarter (should equal item 4.6 above)** | **30,735** | **34,290** |

| 6. | Payments to related parties of the entity and their associates | Current quarter $A'000 |
|---|---|---|
| 6.1 | Aggregate amount of payments to related parties and their associates included in item 1 | 200 |
| 6.2 | Aggregate amount of payments to related parties and their associates included in item 2 | - |

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

**Payment to related parties as disclosed in item 6.1 as follows:**

- $41,992 payments for non-executive director fees for the period;
- $158,302 payments to executive directors for the period, including superannuation paid during the quarter.

For personal use only

| 7. | **Financing facilities**<br>*Note: the term "facility' includes all forms of financing arrangements available to the entity.*<br>*Add notes as necessary for an understanding of the sources of finance available to the entity.* | **Total facility amount at quarter end $A'000** | **Amount drawn at quarter end $A'000** |
|---|---|---|---|
| 7.1 | Loan facilities | - | - |
| 7.2 | Credit standby arrangements | - | - |
| 7.3 | Other (please specify) | - | - |
| 7.4 | **Total financing facilities** | - | - |

| | | |
|---|---|---|
| 7.5 | **Unused financing facilities available at quarter end** | - |

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

| 8. | **Estimated cash available for future operating activities** | **$A'000** |
|---|---|---|
| 8.1 | Net cash from / (used in) operating activities (item 1.9) | (3,542) |
| 8.2 | Cash and cash equivalents at quarter end (item 4.6) | 30,735 |
| 8.3 | Unused finance facilities available at quarter end (item 7.5) | - |
| 8.4 | Total available funding (item 8.2 + item 8.3) | 30,735 |
| 8.5 | **Estimated quarters of funding available (item 8.4 divided by item 8.1)** | 8.68 |

*Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.*

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:
N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:
N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:
N/A

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

For personal use only

## Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 22 October 2026

Authorised by: The Board of Racura Oncology Limited
(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only